A Phase III trial of ARGX-113 in generalized myasthenia gravis

Trial Profile

A Phase III trial of ARGX-113 in generalized myasthenia gravis

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Efgartigimod (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Mar 2018 New trial record
    • 01 Mar 2018 According to an Argenx media release, Company expects to progress ARGX-113 into Phase III development, before the end of the year 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top